A significant reduction in IL-10-producing, tumour-infiltrating DCs and lung cancer incidence was evident in mice harbouring Gal1-silenced tumour cells, emphasizing that Gal1 is a potential target for the development of lung cancer therapeutics [55]. This evidence concerns the gene IL10 and lung cancer.